Drugs, trials and regulatory filings
Every value is shown with the source sentence it was read from.
Latest changes the newest dated facts in the record
| Date | Drug | Change | Sentence it was read from |
|---|---|---|---|
| 2026-08-1025 days ago | AK146D1 | Press release | “IO2.0+ADC2.0疗法|康方Trop2/Nectin4双抗ADC(AK146D1)联合依沃西治疗乳腺癌II期研究首例入组” akesobio.com ↗ |
| 2026-08-0629 days ago | Avacopan | Press release | “A further update on TAVNEOS® (avacopan) in the European Union” csl.com ↗ |
| 2026-08-0530 days ago | Epinephrine | Press release | “Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada” alk.net ↗ |
| 2026-08-0530 days ago | Semaglutide | Press release | “Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray” novonordisk.com ↗ |
| 2026-08-0530 days ago | oveporexton | Press release | “U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1” takeda.com ↗ |
| 2026-08-04Aug 2026 | Botulinum toxin type A | Press release | “Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence” abbvie.com ↗ |
| 2026-08-04Aug 2026 | Botulinic toxin | Press release | “Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence” abbvie.com ↗ |
| 2026-08-04Aug 2026 | Botulinum toxin | Press release | “Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence” abbvie.com ↗ |
| 2026-08-04Aug 2026 | Etonogestrel | Press release | “HCP Action Required: Complete NEXPLANON REMS Certification by August 23, 2026 to Maintain Access to NEXPLANON® (etonogestrel implant) 68 mg” organon.com ↗ |
| 2026-08-04Aug 2026 | Sibeprenlimab | Press release | “Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate,...” otsuka.co.jp ↗ |